Welcome to our dedicated page for Hercules Capital news (Ticker: HTGC), a resource for investors and traders seeking the latest updates and insights on Hercules Capital stock.
Hercules Capital Inc. (NYSE: HTGC) maintains this dedicated news hub for investors tracking its specialty financing activities in technology, life sciences, and renewable energy sectors. Access timely updates on the company’s venture debt solutions, including senior secured loans and strategic partnerships with venture-backed enterprises.
This resource consolidates all official press releases and market-relevant developments, from quarterly earnings to executive leadership updates. Users will find detailed information on financing agreements, portfolio company milestones, and regulatory filings – essential for understanding HTGC’s role in venture growth capital markets.
Key content includes updates on biotechnology sector lending, renewable energy project financing, and structured debt arrangements with emerging technology firms. The curated news flow helps stakeholders monitor how Hercules Capital supports high-growth companies through customized financing solutions.
Bookmark this page for direct access to primary source materials about HTGC’s market activities. Check regularly for insights into how the company navigates opportunities in venture debt financing while maintaining its position as a leading provider of non-dilutive growth capital.
Hercules Capital, Inc. (NYSE: HTGC) announced their participation in the Wells Fargo 2024 Financial Services Investor Conference. The event will provide an opportunity for the financial community to engage with the company's executive management team.
Hercules Capital, Inc. (NYSE: HTGC) reported record Q1 2024 financial results with total gross debt and equity commitments up by 81.7%, gross fundings up by 27.1%, total investment income up by 15.7%, net investment income up by 20.9%, NII providing 125% coverage of base cash distribution, undistributed earnings spillover of $142.7 million, approximately $4.5 billion of assets under management, and conservative balance sheet management.
Hercules Capital, Inc. (NYSE: HTGC) declared a total cash distribution of $0.48 per share for the first quarter of 2024, consisting of a $0.40 per share base distribution and an $0.08 per share supplemental distribution. The company aims to distribute 90% to 100% of its taxable quarterly income or potential annual income. The distributions declared in the first quarter of 2024 were derived from the company's current and accumulated earnings and profits. Hercules also designated 83.85% of Qualified Interest Income for the first quarter of 2024 as exempt from U.S. withholding tax for non-U.S. shareholders.
SynOx Therapeutics has secured a $35m debt financing with Hercules Capital to advance the development and commercialization of emactuzumab, a potential best-in-class CSF1(R) inhibiting monoclonal antibody. The company is conducting a Phase 3 study for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other diseases. The loan facility will support clinical work, registration, and commercialization of emactuzumab, enhancing the company's financial position.
FAQ
What is the current stock price of Hercules Capital (HTGC)?
What is the market cap of Hercules Capital (HTGC)?
